Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EZZ Life Science HoldingsASX:EZZ -5.00%46 5-Year Yield-on-Cost % is 4.30 as of Aug. 07, 2026, which is 162% above its 10-year median of 1.64. GuruFocus rates ASX:EZZ with a GF Score™ of 46/100 and a GF Value™ of A$1.46 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 150 Biotechnology companies, EZZ Life Science Holdings ranks better than 74% on this metric.
EZZ Life Science Holdings (ASX:EZZ) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
EZZ Life Science Holdings 5-Year Yield-on-Cost % Related Terms
ASX:EZZ vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, EZZ Life Science Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EZZ Life Science Holdings 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where EZZ Life Science Holdings's 5-Year Yield-on-Cost % falls into.
EZZ Life Science Holdings 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
EZZ Life Science Holdings (ASX:EZZ) has a 5-Year Yield-on-Cost % of 4.30 as of Aug. 07, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on EZZ Life Science Holdings and its competitors. This is 162% above median its historical median of 1.64. Over the past decade, EZZ Life Science Holdings' 5-Year Yield-on-Cost % has ranged from 0.50 to 10.53. According to the industry distribution chart, EZZ Life Science Holdings ranks #39 out of 150 companies in the Biotechnology industry, placing it in the top 26%.
Is EZZ Life Science Holdings' 5-Year Yield-on-Cost % too high?
EZZ Life Science Holdings' current 5-Year Yield-on-Cost % of 4.30 is 162% above median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 10.53. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.67. EZZ Life Science Holdings' value of 4.30 is 157.5% above this industry median. Based on the distribution chart, EZZ Life Science Holdings ranks #39 out of 150 companies in the Biotechnology industry, which is above the industry midpoint. Overall, EZZ Life Science Holdings has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EZZ Life Science Holdings ranks #39 out of 150 companies for 5-Year Yield-on-Cost %. This puts EZZ Life Science Holdings in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 1.67. EZZ Life Science Holdings' value of 4.30 is 157.5% above this benchmark. Historically, EZZ Life Science Holdings' own 5-Year Yield-on-Cost % has ranged from 0.50 to 10.53 over the past decade. While the company's 10-year median is 1.64 vs. the industry median of 1.67, EZZ Life Science Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.67, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EZZ Life Science Holdings's current 5-Year Yield-on-Cost % of 4.30 is 157.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on EZZ Life Science Holdings and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EZZ Life Science Holdings's current 5-Year Yield-on-Cost % is 4.30, which is 162% above median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.46, compared to a current price of A$0.48 — trading 67.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.30, which is 162% above median its 10-year median of 1.64 and 157.5% above the Biotechnology industry median of 1.67. EZZ Life Science Holdings' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current 5-Year Yield-on-Cost % is 4.30 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?
Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued.
The current stock price of A$0.48 is trading 67.5% below its estimated GF Value™ of A$1.46.
GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.
Key valuation signals for ASX:EZZ:
5-Year Yield-on-Cost %: 4.30 (162% above median its 10-year median of 1.64)
GF Value™: A$1.46 vs. price of A$0.48 (67.5% below fair value)
Industry Position: 157.5% above the Biotechnology median (#39 of 150)
No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
46GF Score
Get the complete analysis for ASX:EZZ
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EZZ has been successfully added to your 
